Your browser doesn't support javascript.
loading
Dynamics and durability of HIV-1 neutralization are determined by viral replication.
Schommers, Philipp; Kim, Dae Sung; Schlotz, Maike; Kreer, Christoph; Eggeling, Ralf; Hake, Anna; Stecher, Melanie; Park, Juyeon; Radford, Caelan E; Dingens, Adam S; Ercanoglu, Meryem S; Gruell, Henning; Odidika, Stanley; Dahlhaus, Marten; Gieselmann, Lutz; Ahmadov, Elvin; Lawong, Rene Y; Heger, Eva; Knops, Elena; Wyen, Christoph; Kümmerle, Tim; Römer, Katja; Scholten, Stefan; Wolf, Timo; Stephan, Christoph; Suárez, Isabelle; Raju, Nagarajan; Adhikari, Anurag; Esser, Stefan; Streeck, Hendrik; Duerr, Ralf; Nanfack, Aubin J; Zolla-Pazner, Susan; Geldmacher, Christof; Geisenberger, Otto; Kroidl, Arne; William, Wiston; Maganga, Lucas; Ntinginya, Nyanda Elias; Georgiev, Ivelin S; Vehreschild, Jörg J; Hoelscher, Michael; Fätkenheuer, Gerd; Lavinder, Jason J; Bloom, Jesse D; Seaman, Michael S; Lehmann, Clara; Pfeifer, Nico; Georgiou, George; Klein, Florian.
Afiliación
  • Schommers P; Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Kim DS; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Schlotz M; Center for Molecular Medicine Cologne (CMMC), Cologne, Germany.
  • Kreer C; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany.
  • Eggeling R; Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
  • Hake A; Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Stecher M; Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Park J; Methods in Medical Informatics, Department of Computer Science, University of Tübingen, Tübingen, Germany.
  • Radford CE; Institute for Bioinformatics and Medical Informatics, University of Tübingen, Tübingen, Germany.
  • Dingens AS; Research Group Computational Biology, Max Planck Institute for Informatics, Saarbrücken, Germany.
  • Ercanoglu MS; Saarland Informatics Campus, Saarbrücken, Germany.
  • Gruell H; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Odidika S; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany.
  • Dahlhaus M; Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
  • Gieselmann L; Molecular and Cellular Biology Graduate Program, University of Washington, and Basic Sciences Division, Fred Hutch Cancer Center, Seattle, WA, USA.
  • Ahmadov E; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Lawong RY; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Heger E; Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Knops E; Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Wyen C; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Kümmerle T; Center for Molecular Medicine Cologne (CMMC), Cologne, Germany.
  • Römer K; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Scholten S; Center for Molecular Medicine Cologne (CMMC), Cologne, Germany.
  • Wolf T; Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Stephan C; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany.
  • Suárez I; Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Raju N; Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Adhikari A; Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Esser S; Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Streeck H; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Duerr R; Praxis am Ebertplatz, Cologne, Germany.
  • Nanfack AJ; Praxis am Ebertplatz, Cologne, Germany.
  • Zolla-Pazner S; Gemeinschaftspraxis Gotenring, Cologne, Germany.
  • Geldmacher C; Praxis Hohenstaufenring, Cologne, Germany.
  • Geisenberger O; Infectious Diseases Division, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.
  • Kroidl A; Infectious Diseases Division, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.
  • William W; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Maganga L; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany.
  • Ntinginya NE; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Georgiev IS; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Vehreschild JJ; Department of Infection and Immunology, Kathmandu Research Institute for Biological Sciences, Lalitpur, Nepal.
  • Hoelscher M; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Fätkenheuer G; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany.
  • Lavinder JJ; Institute of Virology, Medical Faculty, University Bonn, Bonn, Germany.
  • Bloom JD; Department of Microbiology, New York University School of Medicine, New York City, NY, USA.
  • Seaman MS; Department of Medicine, NYU Grossman School of Medicine, New York City, NY, USA.
  • Lehmann C; Vaccine Center, NYU Grossman School of Medicine, New York City, NY, USA.
  • Pfeifer N; Medical Diagnostic Center, Yaoundé, Cameroon.
  • Georgiou G; Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.
  • Klein F; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Nat Med ; 29(11): 2763-2774, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37957379
Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet available, only data from HIV-1 neutralizers-persons with HIV-1 who naturally develop broad and potent nAbs-can inform about the dynamics and durability of nAb responses in humans, knowledge which is crucial for the design of future HIV-1 vaccine regimens. To address this, we assessed HIV-1-neutralizing immunoglobulin G (IgG) from 2,354 persons with HIV-1 on or off antiretroviral therapy (ART). Infection with non-clade B viruses, CD4+ T cell counts <200 µl-1, being off ART and a longer time off ART were independent predictors of a more potent and broad neutralization. In longitudinal analyses, we found nAb half-lives of 9.3 and 16.9 years in individuals with no- or low-level viremia, respectively, and 4.0 years in persons who newly initiated ART. Finally, in a potent HIV-1 neutralizer, we identified lower fractions of serum nAbs and of nAb-encoding memory B cells after ART initiation, suggesting that a decreasing neutralizing serum activity after antigen withdrawal is due to lower levels of nAbs. These results collectively show that HIV-1-neutralizing responses can persist for several years, even at low antigen levels, suggesting that an HIV-1 vaccine may elicit a durable nAb response.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Vacunas contra el SIDA Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Vacunas contra el SIDA Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos